Relistor Injectable Product for Chronic Pain

Chronic pain is a serious issue due to its impact on patient's quality of life and may cause physical instability and mental instability. The most common chronic disease is pain.

Chronic pain occurs in the U.S. in most people at some time during their adult life and affects more than half of all adults at some point in time.

A wide variety of pharmacological and nonpharmacological treatments are used to manage chronic pain. Many of these medications are in their infancy or are not approved by the U.S. Food and Drug Administration for chronic pain management. These discrepancies between current treatment guidelines and clinical practice call for greater research regarding the most effective treatments for chronic pain.

In the vast majority of patients in whom the clinical picture of pain is consistent with the diagnosis of chronic pain a benign, non-dysregulated process like trauma or inflammation is the most likely cause for pain. In patients with multiple symptoms compatible with degenerative joint disease or lumbar stenosis this explanation is less convincing. The high association of all chronic pain complaints in patients with degenerative spinal abnormalities may be due to the mechanical compression of the pain trigger point by the degenerative changes in the spine. However the presence of low back pain does not preclude all serious causes for chronic neck and/or head pain. Chronic neck pain may be associated with any number of pathological conditions, e.g.

Signs of [chronic pain](https://www.withpower.com/clinical-trials/chronic-pain) can include unexplained pain, decreased functioning, and a sense of hopelessness. Individuals experiencing chronic pain have an increased risk of poor health outcomes. Many people who have chronic pain have not discussed their pain. Those who have experienced chronic pain often perceive that no one can understand their pain. They report that their pain is a constant and unexplained problem. Many people who have chronic pain believe their pain to be beyond the control of anything medical professionals can offer.

Many people with disabling pain and a long history of unsuccessful attempts to control it continue to struggle. Recent findings suggests that people with severe, unremitting chronic pain are more likely to achieve pain relief when a combination of a multidisciplinary care program that combines multimodal strategies, as well as supportive therapies as self-management strategies, are utilized.

We want to get more information about why many [chronic pain](https://www.withpower.com/clinical-trials/chronic-pain) patients cannot get enough sleep and why they do not get enough exercise. We want to know what doctors are doing about chronic pain, whether there is a place for alternative medicine in our clinic and in our society. We want to know more about the current status of new treatments in chronic pain and to see the impact they might have on our patients, especially if they do not help them or worsen their pain The information on physical activity might help some chronic pain patients in their treatment of their disease.

Relistor injectables were associated with more adverse events compared with Relistor IM solutions. Relistor injectables were also found to be associated with less pain at injection compared with Relistor IM solutions, suggesting that it is the drug that causes adverse effects.

Relistor injectables are safe and effective for the reduction of intramuscular pain, and all major side effects associated with other opioids are also observed. The most frequent adverse effect observed with the injection of Relistor injectable was local redness in the injection site which can lessen user satisfaction with the injection. Although the risk of developing addiction during the long term use of Relistor is low, the long-term use of Relistor may result in dependence associated with opioid-related side effects.

Results indicate that use of RIKP to relieve [chronic pain](https://www.withpower.com/clinical-trials/chronic-pain) was not associated with significantly higher quality of life outcomes than placebo at 4 months (posttreatment). Improvements in pain, functioning, and physical vitality were observed at 12 months posttreatment, indicating that improvements were maintained 12 months after treatment completion.

Relistor is a new injectable product and it has several attractive features, including ease of use, fast onset of action, low cost, and no detectable pain or systemic effects or addiction. In our opinion, relistor deserves a wider use in clinical practice for improving the patient’s treatment benefits.